Septerna, Inc. (NASDAQ:SEPN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $43.1250.

A number of equities research analysts have weighed in on SEPN shares. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Septerna in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Truist Financial upped their target price on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen downgraded Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th.

Insider Buying and Selling

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This trade represents a 98.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 78,453 shares of company stock valued at $2,192,969 over the last 90 days. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC lifted its position in shares of Septerna by 8.1% during the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after acquiring an additional 100,000 shares during the last quarter. Covestor Ltd lifted its position in shares of Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Septerna by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after acquiring an additional 3,377 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Septerna during the 1st quarter valued at $619,000. Finally, Strs Ohio lifted its position in shares of Septerna by 17.8% during the 1st quarter. Strs Ohio now owns 17,200 shares of the company’s stock valued at $413,000 after acquiring an additional 2,600 shares during the last quarter.

Septerna Price Performance

SEPN opened at $24.75 on Thursday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -30.56 and a beta of 2.21. Septerna has a 1-year low of $8.51 and a 1-year high of $32.63. The business has a 50 day moving average price of $25.09 and a two-hundred day moving average price of $25.46.

Septerna (NASDAQ:SEPN) last released its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. Equities analysts expect that Septerna will post -1.87 EPS for the current fiscal year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.